Southwest Oncology Group S0802: A randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer

Journal of Clinical Oncology

Volumn 32, Issue 23, 2014, Pages 2463-2470

  Allen, Jeffrey W ^a   Moon, James ^b   Redman, Mary ^b   Gadgeel, Shirish M ^c   Kelly, Karen ^d   Mack, Philip C ^d   Saba, Hanna M ^e   Mohamed, Mohamed K ^f   Jahanzeb, Mohammad ^g   Gandara, David R ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Central Illinois CCOP   (United States)

^f MOSES CONE HEALTH SYSTEM   (United States)

^g UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; HEMOGLOBIN; TOPOTECAN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; HYPERTENSION; INFECTION; LEUKOCYTE COUNT; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPHIL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOFT TISSUE DISEASE; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; SMALL CELL LUNG CARCINOMA; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84905867667     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.4109     Document Type: Article

References (34)

1. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006 (Pubitemid 46630948)
2. Owonikoko TK, Behera M, Chen Z, et al: A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 7:866-872, 2012
3. von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent smallcell lung cancer. J Clin Oncol 17:658-667, 1999 (Pubitemid 29075255)
4. O'Brien ME, Ciuleanu TE, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441-5447, 2006 (Pubitemid 46623178)
5. Eckardt JR, von Pawel J, Pujol JL, et al: Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086-2092, 2007 (Pubitemid 46972795)
6. Shah C, Ready N, Perry M, et al: A multicenter phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 57:84-88, 2007 (Pubitemid 46843346)
7. Shipley DL, Hainsworth JD, Spigel DR, et al: Topotecan: Weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC): A Minnie Pearl Cancer Res Network phase II trial. J Clin Oncol 24:384s, 2006 (suppl; abstr 7083)
8. Smit EF, Fokkema E, Biesma B, et al: A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77:347-351, 1998 (Pubitemid 28029555)
9. Yamamoto N, Tsurutani J, Yoshimura N, et al: Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 26:777-781, 2006 (Pubitemid 43206048)
10. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer: The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A:1058-1060, 1994
11. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
12. Pietanza MC, Kadota K, Huberman K, et al: Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 18:1138-1145, 2012
13. van der Lee I, Smit EF, van Putten JW, et al: Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 12:557-561, 2001 (Pubitemid 32472114)
14. Masters GA, Declerck L, Blanke C, et al: Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 21:1550-1555, 2003 (Pubitemid 46594109)
15. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al: Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients: EORTC Lung Cancer Cooperative Group. Eur J Cancer 29A:1720-1722, 1993 (Pubitemid 23275877)
16. Cantwell BM, Bozzino JM, Corris P, et al: The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. Eur J Cancer Clin Oncol 24:123-129, 1988 (Pubitemid 18051175)
17. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
18. Hiratsuka S, Maru Y, Okada A, et al: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 61:1207-1213, 2001 (Pubitemid 32174444)
19. Mandriota SJ, Jussila L, Jeltsch M, et al: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. Embo J 20:672-682, 2001 (Pubitemid 32167632)
20. Hasegawa Y, Takanashi S, Okudera K, et al: Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients. Intern Med 44:26-34, 2005 (Pubitemid 40260037)
21. Salven P, Ruotsalainen T, Mattson K, et al: High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79:144-146, 1998 (Pubitemid 28201685)
22. Kim ES, Serur A, Huang J, et al: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 99:11399-11404, 2002 (Pubitemid 34920937)
23. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506, 2012
24. Gitlitz BJ, Moon J, Glisson BS, et al: Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: A Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 5:1835-1840, 2010
25. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
27. Leighl NB, Raez LE, Besse B, et al: A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinibresistant adenocarcinoma of the lung. J Thorac Oncol 5:1054-1059, 2010
28. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
29. Horn L, Dahlberg SE, Sandler AB, et al: Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006-6011, 2009
30. Ready N, Dudek AZ, Wang XF, et al: CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol 25:400s, 2007 (suppl; abstr 7563)
31. Spigel DR, Greco FA, Zubkus JD, et al: Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 4:1555-1560, 2009
32. Spigel DR, Townley PM, Waterhouse DM, et al: Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the SALUTE trial. J Clin Oncol 29:2215-2222, 2011
33. Jalal S, Bedano P, Einhorn L, et al: Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: A safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol 5:2008-2011, 2010
34. Mountzios G, Emmanouilidis C, Vardakis N, et al: Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group. Lung Cancer 77:146-150, 2012